X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Mocravimod, a sphingosine-1-phosphate (S1P) receptor modulator, is being investigated in a pivotal global Phase 3 study 'treatment of acute myeloid leukemia (AML).
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
KRP203 (mocravimod) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It is currently in phase 3 study for acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant.
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
KRP203 (mocravimod) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This drug is in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications such as AML patients undergoing HCT.
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Mocravimod (also known as KRP203), is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This novel investigational drug has been assessed in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications.
Lead Product(s): Mocravimod,Allogenic Hematopoietic Stem Cell Transplant
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod, a novel S1P receptor modulator, as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT, planned to start in H2 2022.
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
KRP203 (mocravimod), a novel, synthetic, sphingosine 1-phosphate receptor modulator developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients.
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogenic hematopoietic stem cell transplantation (HSCT) for treating AML.
Lead Product(s): Mocravimod
Therapeutic Area: Oncology Product Name: KRP203
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fountain Healthcare
Deal Size: $35.4 million Upfront Cash: Undisclosed
Deal Type: Series A financing October 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
